Aberrant expression of vascular endothelial growth factor (VEGF) is associated with human prostate cancer (PCa) metastasis and poor clinical outcome. We found that both phosphorylation of cyclic AMP-responsive element-binding protein (CREB) and VEGF levels were significantly elevated in patient bone metastatic PCa specimens. A PCa ARCaP progression model demonstrating epithelial-tomesenchymal transition exhibited increased CREB phosphorylation and VEGF expression as ARCaP cells became progressively more mesenchymal and bone-metastatic. Activation of CREB induced, whereas inhibition of CREB blocked, VEGF expression in ARCaP cells. CREB may regulate VEGF transcription via a hypoxia-inducible factor-dependent mechanism in normoxic conditions. Activation of CREB signaling is involved in the coordinated regulation of VEGF and may pre-dispose to PCa bone metastasis.
Introduction
Cyclic AMP (cAMP)-responsive element-binding protein (CREB) signaling is implicated in tumor progression, stimulating growth, conferring apoptotic resistance and supporting angiogenesis (Abramovitch et al., 2004; Kinjo et al., 2005) . In human prostate cancer (PCa), CREB may promote acquisition of neuroendocrine differentiation, associated with androgen-independent progression (Chen et al., 1999; Deeble et al., 2001) . Previous studies from our laboratory and others indicated that CREB signaling regulated osteomimicry in PCa bone metastasis, conferring tumor survival and growth advantages in the bone microenvironment (Huang et al., 2006) . Our results demonstrated that b-2 microglobulin activation of protein kinase A (PKA)-CREB signaling resulted in increased expression of osteocalcin and bone sialoprotein and conferred explosive PCa growth in bone. This communication seeks to demonstrate a functional link between CREB activation and vascular endothelial growth factor (VEGF) expression in PCa bone metastasis.
Increased plasma levels of VEGF correlate with clinical lymph node and skeletal metastasis in PCa (Duque et al., 1999; George et al., 2001; Chen et al., 2004) . Overexpression of VEGF and its receptors is associated with increased tumor vascularity, metastasis, chemoresistance and poor prognosis (Ferrer et al., 1998) . VEGF may affect bone remodeling and facilitate nesting of metastatic cancer cells, crucial for tropism during bone metastasis (Kitagawa et al., 2005) . VEGFinduced activation of VEGFR-1 may promote tumor progression by inducing epithelial-to-mesenchymal transition (EMT) (Yang et al., 2006) , tumor cell migration, invasion and metastasis (Huber et al., 2005) .
VEGF expression is regulated by several factors (Ferrara et al., 2003) . Hypoxia is a major modulator. Hypoxia inducible factor-1 (HIF-1) is a key regulator of transcriptional response to hypoxia, binding the hypoxiaresponse elements (HREs) within VEGF promoter, and activation of VEGF promoter activity (Forsythe et al., 1996) . Optimal control of VEGF expression requires the assembly of a transcriptional complex dynamically coordinated by HIF-1a and its co-activators, including CREB-binding protein (CBP)/p300 (Arany et al., 1996; Niu et al., 2002; Ziel et al., 2004) . In this study, we demonstrate that CREB may be crucial for promoting PCa bone metastasis, inducing VEGF expression via HIF-1-dependent signaling.
Results

Expression of activated CREB in human PCa tissue specimens
To investigate the clinicopathologic significance of CREB, we analysed the immunohistochemical (IHC) protein expression of phosphorylated CREB (p-CREB) in primary and bone metatstatic PCa tissue. We defined well-differentiated PCa as Gleason score p6 and poorly-differentiated PCa as Gleason score X8. In all specimens, activated CREB or nuclear localization of p-CREB expression was undetectable in normal/benign glands (0/5; Figure 1a ) or well-differentiated cancer (0/5; Figure 1b ) but was positively associated with poorly-differentiated cancers (5/5; Figure 1c ). All seven PCa bone metastatic tissue specimens were positive for p-CREB (Figure 1d ).
CREB activation is associated with bone metastatic potential and EMT We used a human PCa ARCaP progression model with EMT properties (Zhau et al., 1996; Xu et al., 2006) to investigate the roles of CREB in PCa bone metastasis. An ARCaP subclone, ARCaP E , has a relatively low propensity for bone metastasis (12.5%) after intracardiac injection, whereas ARCaP M , a bone metastatic derivative of ARCaP closely associated with ARCaP E , has dramatically greater bone metastatic potential (100%) and significantly shorter latency.
Western blot analysis ( Figure 2a ) showed a slight increase in CREB expression in ARCaP M total lysates, with significantly elevated activated CREB. Phosphorylation of activating transcription factor-1, a member of the CREB transcription factor family, was also elevated in ARCaP M cells. p-CREB proteins were more abundant in the ARCaP M nucleus, indicating activation of CREB-dependent transcription. The association of p-CREB expression with increased bone metastatic potential was confirmed in tumor tissues from ARCaP primary and bone metastasis specimens (Figure 2b ).
Serum levels of VEGF in PCa patients positively correlate with bone metastasis A double-blind study measured VEGF levels in sera from 31 patients with non-metastatic PCa versus 24 patients with bone-metastatic PCa. Enzyme-linked immunosorbent assay (ELISA) results indicate a statistically significant difference between the two groups (P ¼ 0.0013). The mean serum level of VEGF in patients with non-bone metastatic PCa was 207.8 pg/ ml (27.3-613.6 pg/ml) and 397.4 pg/ml in patients with bone metastasis (135.6-1,083.7 pg/ml) (Figure 3 ), suggesting that serum VEGF positively correlates with bone-metastatic status. In this study, the average serum prostate-specific antigen (PSA) levels of these two groups of patients were 3.1 ng/ml (incomplete data, n ¼ 19; serum PSA in eight patients was less than 0.1 ng/ml) and 358.1 ng/ml, (n ¼ 24), respectively (P ¼ 0.004). However, the possible effects of treatment on serum VEGF in patients with bone metastasis were not determined.
Activation of CREB induces VEGF transcription in ARCaP cells
We examined differential expression of VEGF transcripts in normoxic ARCaP cells. The human VEGF gene consists of eight exons, and alternative exon splicing generates at least four isoforms: VEGF 121 , VEGF 165 , VEGF 189 and VEGF 206 . VEGF 165 is the predominant isoform, with optimal bioavailability and is responsible for VEGF biological potency (Ferrara et al., 2003) . Reverse transcription-polymerase chain reaction (RT-PCR) analysis showed elevated endogenous mRNA levels of both VEGF 121 and VEGF 165 in ARCaP M cells (Figure 4a ). ELISA of ARCaP-conditioned medium (CM) confirmed a two-fold increase in total VEGF secretion by ARCaP M when compared to ARCaP E cells (Figure 4b ), indicating that VEGF upregulation occurred in normoxic PCa cells and this increased secretion may be associated with EMT and the invasiveness of PCa cells.
Pharmacological and gene transfer experiments in ARCaP E cells explored whether CREB activation is responsible for VEGF expression in PCa cells. Treatment with adenylate cyclase activator forskolin (FSK) rapidly increased VEGF mRNA levels, with more significant induction of VEGF 165 than VEGF 121 ( Figure 5a ). Conversely, a PKA selective inhibitor, H89, reduced VEGF mRNA levels. VEGF ELISA in ARCaP E CM confirmed these results; VEGF secretion was induced by FSK and inhibited by H89 (Figure 5b ). VEGF expression may be controlled by PKA-CREB signaling in normoxic PCa cells. 
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ARCaP E cells were transiently transfected with expression vectors for wild-type CREB (WTCREB), a dominant-negative mutant of CREB (KCREB), using empty vector (pCMV) as the control. KCREB forms an inactive dimer with CREB, blocking its ability to bind cAMP-responsive element (CRE) without interfering with CREB phosphorylation (Yang et al., 1996) . Western blot analysis confirmed expression of WTCREB or KCREB. p-CREB expression was significantly higher in WTCREB-transfected ARCaP E cells and slightly increased in KCREB-transfected cells (Figure 5c ). RT-PCR analysis showed that mRNA levels of VEGF 165 and VEGF 121 were remarkably enhanced by WTCREB but inhibited by KCREB (Figure 5d ), suggesting that CREB could regulate VEGF transcription in ARCaP cells.
HIF-1a is required for CREB regulation of VEGF in ARCaP cells CREB phosphorylation and binding to CRE motif are sufficient for CREB regulation of most target genes (Mayr and Montminy, 2001) . We investigated whether p-CREB directly interacts with putative CRE site(s) within VEGF promoter to regulate VEGF transcription. We performed computational analysis on the 5 0 -flanking sequence of the human VEGF gene using rVista 2.0 (Loots and Ovcharenko, 2004) and TRANSFAC (BIOBASE, Wolfenbu¨ttel, German) . No CRE consensus (TGACGTCA) was found within 6 kb of the 5 0 -flanking region, though a putative CRE site was located about 5 kb upstream from the transcriptional start site, with one base variation (TGAGGTCA) (Figure 6a ). We used a pVEGF-KpnI plasmid (Forsythe et al., 1996) for a reporter assay, with a 2.65 kb fragment of VEGF promoter including a 47-bp HRE sequence (À985 to À939 bp) but not the putative CRE motif (Figure 6a) . ARCaP E cells were transiently transfected with pVEGF-KpnI and then the expression vector for WTCREB or KCREB, with pCMV as control. Luciferase activity showed that WTCREB increased and KCREB inhibited VEGF reporter activity (Figure 6b ), confirming that CREB induces VEGF transcription in normoxic PCa cells and suggesting the putative CRE site may be dispensable for CREB induction of VEGF. CREB may rely on HIF-1a to regulate VEGF expression in PCa cells, as higher basal HIF-1a expression was found in ARCaP M cells compared with normoxic ARCaP E cells (Figure 6c ). ARCaP M also expresses more p-CREB and VEGF (Figures 3a and 4) .
HIF-1a small interfering RNA (siRNA) experiments tested whether HIF-1a-dependent gene transcription is involved in CREB regulation of VEGF transcription. HIF-1a siRNA inhibited endogenous HIF-1a expression in ARCaP E cells. FSK could stimulate VEGF transcription in control-siRNA, but not HIF-1a-siRNA-transfected ARCaP E cells (Figure 6d ). These data suggest that HIF-1a and CREB activation are essential to promote VEGF expression in PCa cells.
Activation of CREB recruits HIF-1a and facilitates its binding to VEGF promoter region To examine whether activated CREB induced intracellular translocation of HIF-1a, ARCaP E nuclear proteins were extracted after FSK treatment (10 mM) at various time periods. Western blot analysis showed dynamic changes in expression of several CREB-interacting transcription factors in the nucleus. Thirty minutes after FSK stimulation, nuclear p-CREB and HIF-1a increased rapidly and increased further at 60 min. CBP expression in the nucleus, which directly interacts with CREB and HIF-1a (Chrivia et al., 1993; Arany et al., 1996) , increased at 30 min and decreased significantly at 60 min, with only a slight increase in nuclear p300 at 30 min (Figure 7a ). CREB activation seems to be accompanied by a dynamic change in nuclear accumulation of HIF-1a, CBP and p300, which may form a transcriptional complex induced by hypoxia or FSK to regulate VEGF promoter activity and HIF-1a-dependent transcription. 
To determine whether CREB activation induces HIF-1a-binding to HRE, we used ELISA to quantify HIF-1a activation and binding to HRE in ARCaP E cells (Figure 7b ). Five micrograms of nuclear extract from COS-7 cells treated with cobalt chloride (CoCl 2 ) was added as a positive control (Jiang et al., 1997) . Wild-type HRE consensus oligonucleotide competitively inhibited binding of COS-7 nuclear extract, which contains HIF-1a to HRE; mutated consensus oligonucleotide did not. ARCaP E nuclear extracts prepared after cells were treated with FSK for various times showed a time-dependent increased binding of ARCaP E nuclear extracts to the HRE consensus that was inhibited by incubation with wild-type but not mutated HRE oligonucleotide. On the contrary, FSK did not induce binding of nuclear extracts to the HRE consensus in KCREB-transfected ARCaP E cells (Supplemental data). The data suggest that CREB activation by FSK induced specific interaction between the ARCaP E nuclear transcription complex, which comprises CREB/HIF-1a and the HRE consensus.
We investigated whether CREB activation promoted specific binding of HIF-1a to VEGF promoter by chromatin immunoprecipitation (ChIP) assay. Fractionated chromatin from controls and FSK-treated ARCaP E cells was immunoprecipitated with HIF-1a antibody or control IgG. From the isolated DNA, a 135-bp region was amplified by PCR (Kong et al., 2005) . Activation of CREB signaling by FSK showed a considerable increase in HIF-1a binding with the HRE region in ARCaP E cells, but not in KCREB-transfected ARCaP E cells (Figure 7c ), demonstrating that CREB activation facilitates association of HIF-1a with VEGF promoter. Further supporting this model, HIF-1a reporter activity was significantly induced in WTCREB-transfected, but not in KCREB-transfected ARCaP E cells in the pHIF1-luc reporter assay (Figure 7d ). 
Discussion
CREB regulates gene expression in a highly tissue-and cell type-specific manner (Impey et al., 2004; Zhang et al., 2005) . Selective activation of CREB could promote local tumor growth and distant metastasis (Huang et al., 2006; Melnikova et al., 2006) . Many modulators of CREB activity are abundant in bone tissues, such as stromal cell-derived factor-1, fibroblast growth factor, transformation growth factor (Johannessen et al., 2004) and b-2-microglobulin (Huang et al., 2006) . The activation status of CREB in ARCaP E and ARCaP M cells suggests that bone microenvironments may induce CREB phosphorylation in bone-homing PCa cells. CREB activation may thereby promote osteomimicry (Huang et al., 2005) and angiogenesis (Abramovitch et al., 2004) through either a direct or indirect mechanisms. In this report, our evidence emphasized the clinicopathological link of CREB-VEGF signaling and human PCa bone metastasis. A variety of genes targeted by CREB activation are implicated in tumorigenesis, such as cyclin D1 (Sabbah et al., 1999) , cyclin A (Desdouets et al., 1995) and Bcl-2 (Arcinas et al., 2001) . In a genome-wide search for the CREB 'regulon' by Impey et al., (2004) , FSK treatment significantly increased VEGF transcription in PC12 cells. These results suggest that VEGF is a novel CREB target. Our analysis of 6 kb of the 5 0 -flanking region of human VEGF gene did not identify any CRE consensus sequence in the proximal region (p2 kb) of this promoter, suggesting that CREB may regulate VEGF transcription without directly binding CRE sites. Indeed, pVEGF-KpnI, containing no CRE consensus, was still responsive to CREB modulation in ARCaP E cells (Figure 6b ). CREB may directly bind CRE site(s) as a complex with other transcription factors to regulate VEGF transcription (Figure 4a ). Cloning and analysis of the 6 kb 5 0 -flanking region of VEGF gene may elucidate the direct role of CREB in regulating VEGF expression.
VEGF expression is depressed under normoxic conditions, mainly by degradation of HIF-1a (Kallio et al., 1999) . However, it has been demonstrated that HIF-1a is a positive factor regulating proliferation in certain tumors under normoxic conditions (Dang et al., 2006) . As ARCaP cells express both endogenous HIF-1a and CREB, it is possible that CREB regulates VEGF in a HIF-1a-dependent manner via formation of a transcription complex in normoxic PCa cells. Coordinated activation of CREB/HIF-1a may thereby directly contribute to the elevated serum VEGF levels in bonemetastatic PCa patients.
CREB-interacting protein (CBP) and its paralogue p300 are key regulators of RNA polymerase II-mediated transcription. By differentially associating with other transcription factors, CBP/p300 specifically regulates gene expression via intrinsic histone acetyltransferase activity (Vo and Goodman, 2001) . CREB phosphorylation promotes interaction between CREB and CBP/p300 to induce CREB-dependent transcription (Chrivia et al., 1993) . Most situations require additional CREB-regulatory partners to recruiting transcriptional machinery . This may explain the highly cell context-dependent regulation of various genes by CREB (Impey et al., 2004; Zhang et al., 2005) . More than 40 transcription factors can interact with CBP/p300 directly. CBP/p300 may be the scaffold for various transcription complexes that regulate target gene expression. Interestingly, both CREB and HIF-1a interact with CBP/p300 (Chrivia et al., 1993; Arany et al., 1996) CBP/p300 may, therefore, be a physical bridge between CREB and HIF-1a (Figure 8 ).
Increased VEGF production/secretion after CREB activation also induces EMT in cancer cells. VEGFbinding and activation of VEGFR-1 in pancreatic cancer cells resulted in morphologic and molecular alterations associated with EMT (Yang et al., 2006) . Our study is the first to implicate CREB-VEGF signaling in EMT and acquisition of invasive phenotypes during PCa progression.
Materials and methods
Collection of serum specimens
After informed consent, serum specimens (10-20 ml) for VEGF analysis were collected from patients with confirmed PCa with or without bone-scan-confirmed metastasis.
IHC staining
Human normal/benign prostatic glands, primary PCa, and bone metastatic PCa tissue specimens were analysed for p-CREB expression by IHC as described (Xu et al., 2006) . Positive p-CREB is defined as >15% positive reaction by the cell population to anti-p-CREB antibody (Cell Signaling, Beverly, MA, USA).
Cell cultures
Human PCa cell lines ARCaP E and ARCaP M were cultured as described previously (Chung et al., 1991; Zhau et al., 1996; Xu et al., 2006) . Serum-starved ARCaP cells were treated with FSK or H89 (Calbiochemicals, San Diego, CA, USA) in serum-free T-medium (Invitrogen, Carlsbad, CA, USA).
Plasmids and transient transfection
The expression vectors for WTCREB and KCREB (Clontech, Mountain View, CA, USA) were transfected into ARCaP E Figure 8 Proposed model for CREB regulation of VEGF expression. CBP or p300 may be scaffold proteins for p-CREB and HIF-1a to form a transcriptional complex on VEGF promoter in response to CREB activation. Reporter assay ARCaP E cells were seeded at a density of 1.5 Â 10 5 cells per well in 12-well plates 24 h before transfection. pVEGF-KpnI (Forsythe et al., 1996) (American Type Culture Collection, Manassas, VA, USA) or pHIF1-luc (Panomics, Fremont, CA, USA) was introduced using lipofectamine 2000. Data were presented as relative luciferase activity (luciferase activity normalized to internal control b-galactosidase activity).
CM preparation Subconfluent cells were cultured in serum-free T-medium for 48 h before CM were collected (Huang et al., 2005) .
VEGF ELISA in patients with PCa VEGF concentration in ARCaP CM, or serum VEGF from PCa patients was analysed using a Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA).
Western blot analysis
Immunoblotting analysis followed standard procedure with anti-CREB and anti-p-CREB (Cell Signaling); anti-CBP, anti-p300 (Santa Cruz Biotechnology); anti-HIF-1a (Upstate, Charlottesville, VA, USA); anti-b-actin (Sigma, St Louis, MO, USA); anti-EF1a (BD Transduction Laboratories, San Diego, CA, USA).
Preparation of nuclear extracts
ARCaP cells were serum-starved overnight and incubated for 2 h with FSK (10 mM) or dimethyl sulfoxide (DMSO). Nuclear proteins were prepared using a NucBuster Protein Extraction Kit (Novagen, San Diego, CA, USA).
RT-PCR
Total RNA (1 mg) was used as template in a reaction using the SuperScriptIII OneStep RT-PCR kit (Invitrogen). The human VEGF primers were described by Bates et al., (2003) . The primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are 5 0 -GTCAGTGGTGGACCTGACCT-3 0 (forward) and 5 0 -AGGGGTCTACATGGCAACTG-3 0 (reverse). The primer pair for human HIF-1a was from Santa Cruz Biotechnology. The thermal profile is 30 cycles for human VEGF or HIF-1a amplification or 20 cycles for GAPDH, with 15 s, 941C; 30 s, 551C; and 60 s, 681C.
DNA-binding assays
An ELISA-based assay (TransAM HIF-1) to analyse HIF-1a/ HRE interaction was used according to the manufacturer's protocol (ActiveMotif, Carlsbad, CA, USA). Nuclear extracts were incubated in 96-well plates precoated with the HRE consensus oligonucleotides. HIF-1a antibody was added to the reactions and an HRP-conjugated secondary antibody was used to quantify the HRE-binding activity of nuclear extracts. The ChIP assay used a ChIP-IT kit (ActiveMotif). ARCaP E cells (1 Â 10 7 ) were serum-starved overnight and replaced with fresh serum-free medium, incubated with FSK (10 mM) or DMSO for 2 h. Chromatin was sheared by enzymatic shearing for 8 min. A portion of chromatin was reversed and used as input DNA. For immunoprecipitation, 2 mg HIF-1a antibody (Santa Cruz Biotechnology) was used. PCR primers for HRE region in VEGF promoter are from published sequences (Kong et al., 2005) . Negative PCR primer pair included in the ChIP kit was used as negative control. PCRs were performed for 30 cycles, with primer concentration as 10 pmol/20 ml.
Data analysis
All data are representative of three or more experiments. Treatment effects were evaluated using a two-sided Student's t-test. Errors are standard error values of averaged results, and values of Po0.05 were taken as a significant difference between means.
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